Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...

Is (ZLAB) Outperforming Other Medical Stocks This Year?

SHANGHAI and SAN FRANCISCO, May 27, 2020 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the.

Regeneron Pharmaceuticals, Inc. (REGN) and Zai Lab Limited (ZLAB) today announced a strategic collaboration for the development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) in mainland China, Hong Kong, Taiwan and Macau. The collaboration will support global clinical development for REGN1979, starting with the ongoing potentially registrational Phase 2 program in B-cell non-Hodgkin lymphoma (B-NHL). Additionally, if REGN1979 is approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in this region.

Fund releases portfolio for the 1st quarter Continue reading...

Stock soars on promising early trial data for key drugs Continue reading...

Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for omadacycline for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). “This is another important step in the development of Zai as a fully-integrated biopharmaceutical company,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

SHANGHAI, China and SAN FRANCISCO, April 30, 2020 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company,.

SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company,.

SHANGHAI, China, and SAN FRANCISCO, May 06, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center.

Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the China National Medical Products Administration (NMPA) has accepted its supplemental New Drug Application (sNDA) for ZEJULA® (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Zai Lab Ltd. (NASDAQ:ZLAB) will be discussing their earnings results in their 2019 Second Half Earnings call to be held on March 19, 2020 at 8:30 AM Eastern ...

Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority review status to the supplemental New Drug Application (sNDA) for ZEJULA (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. “China NMPA’s decision to grant priority review to our sNDA for ZEJULA underscores both the urgency of the medical need and the potential of ZEJULA as an innovative therapeutic option in the first-line setting for ovarian cancer patients,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab.

As of late, it has definitely been a great time to be an investor in Zai Lab.

Zai Lab Limited (“Zai Lab”) (ZLAB), an innovative commercial-stage biopharmaceutical company, today announced positive topline results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) who are in a complete or partial response to platinum-based chemotherapy. The NORA study randomized 265 patients at 2:1 to receive ZEJULA or placebo until disease progression.

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Novocure and Zai Lab announced that China NMPA approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma.

-- Company to host Conference Call and Webcast on March 19, 2020 at 8:30 a.m. ET SHANGHAI, China and SAN FRANCISCO, March 05, 2020 -- Zai Lab Limited (NASDAQ: ZLAB), a China.

Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced financial results for the twelve months ended December 31, 2019 and corporate updates.

Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter baumannii infections.